Oral semaglutide shows promise in children and teens with type 2 diabetes

Novo Nordisk reported clinical trial data suggesting that oral semaglutide could become the first oral GLP-1 receptor agonist medicine approved for children and adolescents with type 2 diabetes ^[1]. The announcement, dated April 23, 2026, describes the drug's "potential" to fill this role, but it is a development update rather than a formal regulatory approval ^[1].

Semaglutide already has a long history of approvals in adults. The injectable form, sold as Ozempic, was first approved for adults with type 2 diabetes in December 2017 and later approved to reduce cardiovascular risk and slow worsening kidney disease in adults with type 2 diabetes ^[1]. An oral tablet form of semaglutide has also existed for adults since 2019 under the brand name Rybelsus, and a newer, higher-dose oral formulation was approved in December 2024 before being rebranded as Ozempic tablets in January 2026 ^[1]. None of these approvals, so far, cover children or teenagers ^[1].

The source describing the pediatric data is a company news release listed in a drug-history timeline, and it does not include specific numbers such as trial size, dosing, blood sugar results, or safety findings in young patients ^[1]. Because those details are not included in the available source, they are not yet known from what has been reported here.

Why it matters for patients

Options for treating type 2 diabetes in children and teenagers are limited compared with options for adults ^[1]. If oral semaglutide is eventually approved for this age group, it could give families and doctors an additional tool, and one that comes as a pill rather than an injection, which may matter for children who are hesitant about needles.

For now, families of children or teens with type 2 diabetes should understand that this is trial data pointing toward possible future use, not a current approval. Ozempic tablets and Rybelsus are approved only for adults, based on the approval history described in the source ^[1]. Any decision about treating a child or teenager for type 2 diabetes today would need to rely on medicines and dosing already approved for that age group, since the pediatric use of oral semaglutide has not been authorized by regulators according to this source ^[1].

It is also worth noting that semaglutide products carry a boxed warning about thyroid C-cell tumors, along with warnings about pancreatitis, gallbladder disease, and other risks in adults ^[1]. Whether these warnings would apply the same way in children, or whether additional safety data would be needed, is not addressed in the available source.

What happens next

The source does not specify a timeline for when, or whether, oral semaglutide might be submitted for approval in children and adolescents with type 2 diabetes, nor does it name a target decision date from the Food and Drug Administration ^[1]. Separately, the same approval-history timeline shows that Novo Nordisk has been making other changes to its US semaglutide business this year, including price reductions for Wegovy, Ozempic, and Rybelsus in February 2026, expanded access through the telehealth company Hims & Hers in March 2026, and the broader rollout of the Ozempic tablet form in the second quarter of 2026 ^[1]. These changes are separate from the pediatric development news, but they show a period of rapid change in how semaglutide products are priced, packaged, and distributed in the United States ^[1]. Readers who want updates on pediatric approval status will need to watch for further company or FDA announcements, since none are dated in the source provided.